Clinical Trial

Benmelstobart, Anlotinib and Chemotherapy as First-line Treatment for Extensive-stage Small-cell Lung Cancer

Not Yet Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
The goal of this clinical trial is to evaluate the efficacy and safety of benmelstobart in combination with anlotinib and chemotherapy sequential benmelstobart in combination with anlotinib for the first-line treatment of extensive-stage small cell lung cancer.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-04-09.
Trial Details
NCT Number NCT06931145
Lead Sponsor Peking Union Medical College Hospital
Collaborators: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Conditions Extensive-stage Small Cell Lung Cancer
Enrollment 50 participants
Start Date 2025-04-15
Primary Completion 2027-04-30 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-04-23